U.S. Markets close in 2 hrs 32 mins

Free Technical Reports on Portola Pharma and Three Additional Biotech Equities

Stock Research Monitor: PSTI, REPH, and REGN

LONDON, UK / ACCESSWIRE / July 19, 2018 / If you want a free Stock Review on PTLA sign up now at www.wallstequities.com/registration. WallStEquities.com revisits the Biotech space, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are the following equities: Pluristem Therapeutics Inc. (NASDAQ: PSTI), Portola Pharmaceuticals Inc. (NASDAQ: PTLA), Recro Pharma Inc. (NASDAQ: REPH), and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN). All you have to do is sign up today for this free limited time offer by clicking the link below.


Pluristem Therapeutics

On Wednesday, shares in Haifa, Israel-based Pluristem Therapeutics Inc. saw a decline of 2.34%, ending the day at $1.25. The stock recorded a trading volume of 129,110 shares. The Company's shares have advanced 1.63% over the previous three months and 4.17% over the past year. The stock is trading below its 50-day moving average by 5.26%. Moreover, shares of Pluristem Therapeutics, which together with its subsidiary, Pluristem Ltd, operates as a bio-therapeutics company in Israel, have a Relative Strength Index (RSI) of 44.48.

On July 09th, 2018, Pluristem Therapeutics announced that it has entered into a strategic collaboration with Thermo Fisher Scientific to advance fundamental knowledge of cell therapy industrialization and to improve quality control of the end-to-end supply chain. Together, the companies hope to transform cell therapy manufacturing into a large-scale, high-capacity industry that will enable the production of millions of therapeutic doses of regenerative medicines. Get the full research report on PSTI for free by clicking below at:


Portola Pharmaceuticals

Shares in South San Francisco, California headquartered Portola Pharmaceuticals Inc. ended the day flat at $40.10 with a total trading volume of 813,563 shares. In the previous three months, the stock has gained 20.24%. The Company's shares are trading below their 50-day moving average by 1.94%. Furthermore, shares of Portola Pharma, which develops and commercializes therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation, have an RSI of 48.66.

On July 03rd, 2018, Portola Pharma announced that on June 27th, 2018, the Compensation Committee of the Board of Directors approved, effective as of June 29th, 2018, the grant of an inducement stock option to purchase 87,500 shares of common stock and an award in the form of 25,000 restricted stock units to Glenn Brame, the Company's newly appointed Senior Vice President - Technical Operations. Today's complimentary research report on PTLA is accessible at:


Recro Pharma

At the close of trading on Wednesday, shares in Malvern, Pennsylvania-based Recro Pharma Inc. finished 0.91% lower at $5.44 with a total trading volume of 74,068 shares. The stock has advanced 3.03% in the last month. The Company's shares are trading below their 50-day moving average by 20.99%. Additionally, shares of Recro Pharma, which engages in developing non-opioid products for the treatment of acute pain primarily in the US, have an RSI of 35.36.

On June 26th, 2018, Recro Pharma announced the publication of a previously reported Phase-III clinical data for intravenous meloxicam for the treatment of pain following abdominoplasty surgery. The article, titled “Efficacy and Safety of Intravenous Meloxicam in Subjects with Moderate to Severe Pain Following Abdominoplasty,” was published online in the Plastic and Reconstructive Surgery Global Open. Register now for your free research document on REPH at:


Regeneron Pharmaceuticals

Tarrytown, New York headquartered Regeneron Pharmaceuticals Inc.'s shares recorded a trading volume of 456,596 shares at the end of yesterday's session. The stock closed the day 0.15% higher at $365.98. The Company's shares have advanced 15.96% in the past month and 13.87% in the previous three months. The stock is trading above its 50-day and 200-day moving averages by 13.69% and 2.81%, respectively. Additionally, shares of Regeneron Pharma, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide, have an RSI of 72.51.

On July 09th, 2018, Regeneron Pharma announced that it will report its Q2 2018 financial and operating results on August 02nd, 2018, before the US financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 a.m. ET that same day. A link to the webcast will be available under the “Investors and Media” page of the Company's website. Click on the link below and see our free report REGN at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com

Phone number: 21 32 044 483

Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities